Dataset Information

The Behaviour of Serum Survivin in Patients With Lupus Nephritis.

ABSTRACT:

Background

Systemic lupus erythematosus (SLE) is a chronic, multi phenotypic, autoimmune inflammatory disease and renal involvement significantly worsens its prognosis. Apoptosis dysregulation plays a key pathogenic role. Survivin, a protein from the apoptosis inhibitors family, has been considered a promising strategy in cancer therapy and evaluated as one of the regulatory pathways in the scenario of immune-mediated disorders.

Objective

This study aims to explore survivin behaviour in SLE patients with lupus nephritis (LN), assessing its potential as a therapeutic and prognostic biomarker.

Methods

297 SLE patients were classified based on the American College of Rheumatology (ACR) 1997 criteria, from 2000 to 2015. In a cross-sectional study, the serum level of survivin was measured by an ELISA test and compared between 200 SLE individuals and healthy controls. In a longitudinal cohort, 97 patients with active LN had the concentration of survinin measured, before and after treatment with cyclophosphamide pulse therapy.

Results

The serum concentration of survivin was significantly lower in the SLE group than in healthy controls, regardless of concomitant NL or disease activity. The longitudinal evaluation revealed a significant reduction in survivin serum level after treatment. However, survivin rates were not able to discriminate groups that achieved remission from those that maintained nephritis activity.

Conclusion

Our study suggests that survivin levels in SLE patients are lower than in the general population. Even so, its use as a biomarker in SLE seems limited, not reflecting disease activity or response to LN treatment, as in other contexts.

SUBMITTER: Lisboa RV

PROVIDER: S-EPMC9597205 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Behaviour of Serum Survivin in Patients With Lupus Nephritis.

Lisboa Renata Valente RV de Oliveira Fabiola Reis FR Quaresma Thaise Oliveira TO de Almeida Rafael Moura RM Ribeiro Oliveira Rene Donizeti RD Junior Paulo Louzada PL

Biomarker insights 20221022

<h4>Background</h4>Systemic lupus erythematosus (SLE) is a chronic, multi phenotypic, autoimmune inflammatory disease and renal involvement significantly worsens its prognosis. Apoptosis dysregulation plays a key pathogenic role. Survivin, a protein from the apoptosis inhibitors family, has been considered a promising strategy in cancer therapy and evaluated as one of the regulatory pathways in the scenario of immune-mediated disorders.<h4>Objective</h4>This study aims to explore survivin behavi ...[more]

PMID: 36311208

Similar Datasets

Project description:BackgroundLupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE), causing considerable morbidity and even mortality. Previous studies had shown the potential of metabolic profiling in the diagnosis of SLE or LN. However, few metabonomics studies have attempted to distinguish SLE from LN based on metabolic changes. The current study was designed to find new candidate serum signatures that could differentiate LN from SLE patients using a non-targeted metabonomics method based on ultra high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).MethodMetabolic profiling of sera obtained from 21 healthy controls, 52 SLE patients and 43 LN patients. We used SPSS 25.0 for statistical analysis. Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and metabolic pathway analysis were used to analyze the metabolic data.ResultsUpon comparison of SLE and LN groups, 28 differential metabolites were detected, the majority of which were lipids and amino acids. Glycerolphospholipid metabolism, pentose and glucuronate interconversions and porphyrin and chlorophyll metabolism were obviously enriched in LN patients versus those with SLE. Among the 28 characteristic metabolites, five key serum metabolites including SM d34:2, DG (18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/0:0), nervonic acid, Cer-NS d27:4, and PC (18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z) performed higher diagnostic performance in discriminating LN from SLE (all AUC > 0.75). Moreover, combined analysis of neuritic acid, C1q, and CysC (AUC = 0.916) produced the best combined diagnosis.ConclusionThis study identified five serum metabolites that are potential indicators for the differential diagnosis of SLE and LN. Glycerolphospholipid metabolism may play an important role in the development of SLE to LN. The metabolites we screened can provide more references for the diagnosis of LN and more support for the pathophysiological study of SLE progressed to LN.

Project description:ObjectiveThe aim of this study is to examine the relationship between serum complement component 4 (C4) levels and tubular atrophy in patients with lupus nephritis (LN).MethodsPatients diagnosed with LN through renal biopsy were retrospectively analyzed and categorized into two groups: the tubular atrophy group (TA group) and the non-tubular atrophy group (non-TA group). Demographic data, clinical characteristics, and pathological findings were compared between the groups. Logistic regression and spline smoothing plot analysis, utilizing the generalized additive mixed model, were employed to investigate the relationship between serum C4 levels and the occurrence of tubular atrophy.ResultsA total of 129 patients were included in the study, with 57 (44.2%) identified as having tubular atrophy (TA group), while the remaining 72 patients did not present with tubular atrophy (non-TA group). Patients in the TA group exhibited higher serum C4 levels (p = 0.008) and lower eGFR (p = 0.001) compared to those in the non-TA group. Pathological findings revealed that the TA group had a higher incidence of mesangial hypercellularity (p = 0.041), endocapillary hypercellularity (85.96% vs. 68.06%, p = 0.018), interstitial inflammation (p < 0.018), karyorrhexis (78.95% vs. 59.72%, p = 0.02), and arteriole hypertrophy (66.67% vs. 38.89%, p = 0.02). Multivariate logistic regression analysis revealed that elevated serum C4 levels were associated with tubular atrophy in patients with LN (OR = 1.069, 95% CI 1.001 - 1.141, p = 0.048). Furthermore, spline smoothing analysis using the generalized additive mixed model indicated a linear relationship between serum C4 levels and the occurrence of tubular atrophy events. This linear relationship remained consistent across various stratifications, including age, hypertension, leukocyte count, hemoglobin levels, and estimated glomerular filtration rate (eGFR).ConclusionSerum C4 levels demonstrate a significant correlation with the presence of tubular atrophy in patients diagnosed with LN.

Dataset Information

The Behaviour of Serum Survivin in Patients With Lupus Nephritis.

Background

Objective

Methods

Results

Conclusion

Publications

The Behaviour of Serum Survivin in Patients With Lupus Nephritis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets